Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

NCT07244003 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a combination of three medications (Metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists) can help lower blood sugar levels in adults with type 2 diabetes who currently have poor blood sugar control.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 430 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-03 · est. completion 2028-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07244003 ↗

Description as written by the study sponsor.

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Treatments tested

Metformin Drug

The dosage of metformin hydrochloride was consistent with baseline.
Triple Therapy of Other Oral Antidiabetic Drugs Drug

The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions.
ganagliflozin Drug

Ganagliflozin tablet : 50mg/d.
liraglutide Drug

Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week.

Main thing measured	The change of HbA1c compared to the baseline
Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions studied	T2DM (Type 2 Diabetes Mellitus)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07244003 ↗